Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL7122938 | 0.87 | SLC6A2 (0.45) | CYP2D6SLC6A4 | |
| Oxalic Acid SCHEMBL7312260 | 0.83 | SLC6A9 (0.47) | SLC6A9ALDH1A1SLC6A4HRH3KDM4E | |
| SCHEMBL5431801 | 0.79 | SLC6A4 (0.46) | CYP2D6CYP2C19SLC6A4MEN1KMT2A | |
| Oxalic Acid SCHEMBL7313636 | 0.77 | SLC6A9 (0.47) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6721958 | 0.76 | SLC6A4 (0.52) | SLC6A9SLC6A4HRH3 | |
| Oxalic Acid SCHEMBL7313643 | 0.75 | SLC6A9 (0.47) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| Oxalic Acid SCHEMBL7316393 | 0.73 | SLC6A9 (0.51) | SLC6A9ALDH1A1SLC6A4HRH3KDM4E | |
| SCHEMBL7169436 | 0.72 | SLC6A4 (0.52) | SLC6A9CYP2D6CYP2C19SLC6A4HRH3 | |
| SCHEMBL17835738 | 0.71 | SLC6A9 (0.56) | SLC6A9 | |
| SCHEMBL17835592 | 0.71 | SLC6A9 (0.56) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266882-A1 | Aryloxypropylamines as chemosensitizing agents in the treatment of cancer | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2004-12-30 | — | — | US | claimed |
| EP-1425002-A1 | ARYLOXYPROPYLAMINES AS CHEMOSENSITIZING AGENTS IN THE TREATMENT OF CANCER | Ramot at Tel Aviv University Ltd. (IL) | 2004-06-09 | — | — | EP | claimed |
| US-20040054014-A1 | Method and pharmaceutical compositions forthe treatment of cancer | RAMOT AT TEL AVIV UNIVERSITY LTD. | 2004-03-18 | — | — | US | claimed |
| US-6630454-B2 | Method and pharmaceutical composition for the treatment of cancer | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2003-10-07 | — | — | US | claimed |
| US-20030087964-A1 | Method and pharmaceutical composition for the treatment of cancer | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. | 2003-05-08 | — | — | US | claimed |
| WO-2003022258-A1 | ARYLOXYPROPYLAMINES AS CHEMOSENSITIZING AGENT IN THE TREATMENT OF CANCER | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2003-03-20 | — | — | WO | claimed |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-8080553-B2 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-12-20 | — | — | US | disclosed |
| EP-2301628-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2218442-A1 | Methods, compositions, and kits for the treatment of ophthalmic disorders | CombinatoRx, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20100081713-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | CombinatoRx, (Singapore) Pte. Ltd. | 2010-04-01 | — | — | US | disclosed |
| EP-2070550-A1 | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases | Combinatorx, Incorporated (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1670427-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2009-01-07 | — | — | EP | disclosed |
| US-6630454-B2 | Method and pharmaceutical composition for the treatment of cancer | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2003-10-07 | — | — | US | disclosed |
| US-20030087964-A1 | Method and pharmaceutical composition for the treatment of cancer | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. | 2003-05-08 | — | — | US | disclosed |
| WO-2003022258-A1 | ARYLOXYPROPYLAMINES AS CHEMOSENSITIZING AGENT IN THE TREATMENT OF CANCER | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2003-03-20 | — | — | WO | disclosed |
| US-4626549-A | Treatment of obesity with aryloxyphenylpropylamines | ELI LILLY AND COMPANY (US) | 1986-12-02 | — | — | US | disclosed |
| US-4314081-A | ANTIDEPRESSANTS | ELI LILLY AND COMPANY (US) | 1982-02-02 | — | — | US | disclosed |
| US-4194009-A | ANTIDEPRESSANT | ELI LILLY AND COMPANY (US) | 1980-03-18 | — | — | US | disclosed |
| US-4018895-A | Aryloxyphenylpropylamines in treating depression | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054014-A1 | Method and pharmaceutical compositions forthe treatment of cancer | ABCC1, ABCB1, SLC11A2 | SLC6A4 340/4885SLC6A9 1153/4885ALDH1A1 290/4885 |
| US-20030087964-A1 | Method and pharmaceutical composition for the treatment of cancer | PNMT, ABCC1, HNMT | SLC6A4 596/4885SLC6A9 2429/4885ALDH1A1 530/4885 |
| US-20040266882-A1 | Aryloxypropylamines as chemosensitizing agents in the treatment of cancer | ABCC1, PNMT, ABCB1 | SLC6A4 280/4885SLC6A9 2252/4885ALDH1A1 133/4885 |
| US-20100081713-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | IFNG, IL5, HAVCR2 | SLC6A4 4506/4885SLC6A9 4747/4885ALDH1A1 2248/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | SLC6A4 3269/4885SLC6A9 4836/4885ALDH1A1 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.